News headlines about Exelixis (NASDAQ:EXEL) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Exelixis earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.5792849186039 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Worth Watching Stocks: Teradyne Inc. (NYSE:TER), Exelixis, Inc. (NASDAQ:EXEL) – The Oracle Examiner (oracleexaminer.com)
- Commit To Purchase Exelixis At $13, Earn 11.2% Using Options – Nasdaq (nasdaq.com)
- Exelixis, Inc. (EXEL) Given Average Rating of “Hold” by Analysts (americanbankingnews.com)
- Exelixis, Inc. (NASDAQ:EXEL) – Is The Stock Worthy? – Nasdaq Journal (nasdaqjournal.com)
- Volatile Stock Characteristics – Exelixis Inc (NASDAQ: EXEL) – Stocks Pen (stockspen.com)
Exelixis (EXEL) traded up $0.07 on Wednesday, hitting $24.87. 3,315,110 shares of the company’s stock were exchanged, compared to its average volume of 2,950,146. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50. The company has a market capitalization of $7,360.00, a price-to-earnings ratio of 50.76, a P/E/G ratio of 1.35 and a beta of 1.96.
EXEL has been the topic of a number of analyst reports. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, January 5th. SunTrust Banks reissued a “buy” rating and set a $38.00 target price on shares of Exelixis in a research report on Thursday, December 21st. Cann reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, March 8th. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research note on Wednesday, January 17th. Finally, Stifel Nicolaus raised their price objective on shares of Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $34.10.
In other Exelixis news, Director Vincent T. Marchesi sold 15,000 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $24.73, for a total transaction of $370,950.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Patrick J. Haley sold 45,029 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $27.13, for a total transaction of $1,221,636.77. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 120,029 shares of company stock worth $3,158,287. Company insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.